Jiangsu Hansoh ADC HS-20093 holds potential to set new standard in SCLC second-line treatment in…
HS-20093: A breakthrough ADC poised to redefine second-line SCLC care in China, strengthening Jiangsu Hansoh's oncology leadership…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Chinese oncology market
Sugemalimab approval in China makes it only second drug approved globally for ENKTL: GlobalData
GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China